池田 圭吾 いけだ けいご 先生

来歴等

略歴

1995年 順天堂大学医学部 卒業、同年医師国家試験 合格
1995年 順天堂大学医学部附属順天堂医院 内科 臨床研修
1998年 順天堂大学医学部膠原病学内科学講座 入局、同大学院 入学
2002年 順天堂大学医学部大学院医学研究科 卒業、医学博士 授与
2002年 日本内科学会 認定内科医
2003年 佐々木研究所附属杏雲堂病院 内科 医員
2003年 日本リウマチ学会 リウマチ専門医、日本リウマチ財団 登録医
2004年 米国フロリダ大学歯学部口腔生物学科 Dr. Edward K.L. Chan研究室 博士研究員
2009年 日本内科学会 指導医
2010年 順天堂大学医学部膠原病学内科学講座 助教
2010年 日本リウマチ学会 リウマチ指導医
2010年 順天堂大学医学部附属浦安病院 膠原病内科 准教授
2015年 日本リウマチ学会 評議員
2018年 日本内科学会 総合内科専門医
2019年 日本臨床免疫学会 免疫療法認定医

論文

• 1. Type 1 interferon suppresses expression and glucocorticoid induction of glucocorticoid-induced leucine zipper (GILZ). Front. Immunol. 2022 Nov 23.

  Dankers W, Northcott M, Bennett T, D’Cruz A, Sherlock R, Gearing LJ, Hertzog P, Russ B, Miceli I, Scheer S, Fujishiro M, Hayakawa K, Ikeda K, Morand EF, Jones SA.

• 2. Exposure of female NZBWF1 mice to imiquimod induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset. Clin Exp Immunol. 2022 Feb 2.

  Hayakawa K, Fujishiro M, Yoshida Y, Kataoka Y, Sakuma S, Nishi T, Ikeda K, Morimoto S, Takamori K, Sekigawa I.

• 3. Recurrence in long-term survivor of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis: case series and literature review. Mod Rheumatol Case Rep. 2021 Feb 9.

  Suzuki S, Ikeda K, Yamaji K, Tamura N, Morimoto S.

• 4. Metformin repositioning in rheumatoid arthritis. Clin Exp Rheumatol. 2021 Jul-Aug; 39(4): 763-768.

  Matsuoka Y, Morimoto S, Fujishiro M, Hayakawa K, Kataoka Y, Suzuki S, Ikeda K, Takamori K, Yamaji K, Tamura N.

• 5. Complication of COVID-19 during remission induction therapy against anti-MDA5 antibody positive dermatomyositis. Rheumatol Adv Pract. 2020 Nov 17. rkaa068.

  Kogami M, Suzuki S, Nanjo Y, Ikeda K, Tamura N, Sasaki S, Morimoto S.

• 6. Social defeat stress exacerbates atopic dermatitis through downregulation of DNA methyltransferase 1 and upregulation of C_C motif chemokine receptor 7 in skin dendritic cells. Biochem Biophys Res Commun. 2020 Sep; 529(4): 1073-1079.

  Yoshida Y, Hayakawa K, Fujishiro M, Ikeda K, Tsushima H, Hirai T, Kawasaki M, Tominaga M, Suga Y, Takamori K, Sekigawa I, Morimoto S.

• 7. A Case of MPO-ANCA Positive Systemic Lupus Erythematosus Developed into Acute Kidney Injury. Arch Clin Med Case Rep. 2019 Sep; 3(6): 560-566.

  Suzuki S, Ogiwara K, Nishi T, Sakuma S, Akira M, Iwasaki M, Honda D, Takahara H, Ikeda K, Yamaji K, Tamura N, Rinno H, Morimoto S.

• 8. MicroRNA-766-3p Contributes to Anti-Inflammatory Responses through the Indirect Inhibition of NF-κB Signaling. Int. J. Mol. Sci. 2019 Feb; 20(4), 809.

  Hayakawa K, Kawasaki M, Hirai T, Yoshida Y, Tsushima H, Fujishiro M, Ikeda K, Morimoto S, Takamori K, Sekigawa I.

• 9. Securely collecting multidimensional health information from patients with rheumatoid arthritis using smart device technology: Beneficial effect for physicians and patients. Musculoskeletal Care. 2018 Jun 28.

  Ikeda K, Sekiguchi N, Hirai T, Tanji K, Zushi A, Inoue M, Takasago M, Komatsu T, Morimoto S, Yamaji K, Takamori K, Tamura N, Sekigawa I.

• 10. Aortic Aneurysm as a Complication of Granulomatosis with Polyangiitis Successfully Treated with Prednisolone and Cyclophosphamide: A Case Report and Review of the Literature. Case Rep Rheumatol. 2018 Jun 5.

  Niimi N, Miyashita T, Tanji K, Hirai T, Watanabe K, Ikeda K, Morimoto S, Sekigawa I.

• 11. Connective tissue growth factor neutralization aggravates the psoriasis skin lesion: the analysis of psoriasis model mice and patients. Ann Dermatol. 2018 Feb; 30(1): 47-53.

  Hayakawa K, Ikeda K, Fujishiro M, Yoshida Y, Hirai T, Tsushima H, Miyashita T, Morimoto S, Suga Y, Takamori K, Ogawa H, Sekigawa I.

• 12. Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. Inflamm Regen. 2018 Jan 8; 38:1.

  Hirai T, Ikeda K, Tsushima H, Fujishiro M, Hayakawa K, Yoshida Y, Morimoto S, Yamaji K, Takasaki Y, Takamori K, Tamura N, Sekigawa I.

• 13. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017 Aug 23;18(1):42.

  Ikeda K, Hayakawa K, Fujishiro M, Kawasaki M, Hirai T, Tsushima H, Miyashita T, Suzuki S, Morimoto S, Tamura N, Takamori K, Ogawa H, Sekigawa I.

• 14. Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis. Autoimmunity. 2017 Jul 6:1-7.

  Tsushima H, Morimoto S, Fujishiro M, Yoshida Y, Hayakawa K, Hirai T, Miyashita T, Ikeda K, Yamaji K, Takamori K, Takasaki Y, Sekigawa I, Tamura N.

• 15. Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies. Intern Med. 2017 May; 56(10): 1147-1152.

  Ikeda K, Watanabe K, Hirai T, Tanji K, Miyashita T, Nakajima S, Uomori K, Morimoto S, Takamori K, Ogawa H, Takasaki Y, Sekigawa I.

• 16. Intestinal perforation due to hemorrhagic Cytomegalovirus enteritis in a patient with severe uncontrolled lupus nephritis: a case and review of the literature. Rheumatol Int. 2017 Aug; 37(8): 1395-1399.

  Ikeda K, Nakajima S, Tanji K, Hirai T, Uomori K, Morimoto S, Tomita S, Fukunaga M, Tamura N, Sekigawa I.

• 17. The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study. Clin Rheumatol. 2017 Jan; 36(1): 51-58.

  Hirai T, Ikeda K, Fujishiro M, Tsushima H, Hayakawa K, Suzuki S, Yamaguchi A, Nozawa K, Morimoto S, Takasaki Y, Ogawa H, Takamori K, Tamura N, Sekigawa I.

• 18. A re-evaluation of anti-NA-14 antibodies in patients with primary Sj_gren's syndrome: Significant role of interferon-γ in the production of autoantibodies against NA-14. Autoimmunity. 2016 Jun 21: 1-10.

  Uomori K, Nozawa K, Ikeda K, Doe K, Yamada Y, Yamaguchi A, Fujishiro M, Kawasaki M, Morimoto S, Takamori K, Sekigawa I, Chan EKL, Takasaki Y.

• 19. Inhibition of each module of connective tissue growth factor as a potential therapeutic target for rheumatoid arthritis. Autoimmunity. 2015 Nov 19: 1-6.

  Miyashita T, Morimoto S, Fujishiro M, Hayakawa K, Suzuki S, Ikeda K, Miyazawa K, Morioka M, Takamori K, Ogawa H, Sekigawa I, Takasaki Y.

• 20. Epstein-Barr Virus-Positive Multiple Myeloma Developing After Immunosuppressant Therapy for Rheumatoid Arthritis − A Case Report and Literature Review. Int J Clin Exp Pathol. 2015 Feb 1; 8(2): 2090-102.

  Sekiguchi Y, Shimada A, Ichikawa K, Wakabayashi M, Sugimoto K, Ikeda K, Sekigawa I, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y, Komatsu N, Noguchi M.

• 21. Inhibition of the insulin-like growth factor system is a potential therapy for rheumatoid arthritis. Autoimmunity. 2014 Oct 29: 1-8.

  Suzuki S, Morimoto S, Fujishiro M, Kawasaki M, Hayakawa K, Miyashita T, Ikeda K, Miyazawa K, Yanagida M, Takamori K, Ogawa H, Sekigawa I, Takasaki Y.

• 22. Rapid onset of small intestinal perforation after successful steroid treatment in eosinophilic granulomatosis with polyangiitis. Mod Rheumatol. 2014 Aug 11: 1-3.

  Ikeda K, Takasaki Y, Sekigawa I.

• 23. Antibody against chromatin assembly factor-1 is a novel autoantibody specifically recognized in systemic lupus erythematosus. Lupus. 2014 Sep; 23(10): 1031-41.

  Doe K, Nozawa K, Hiruma K, Yamada Y, Matsuki Y, Nakano S, Ogasawara M, Nakano H, Ikeda T, Ikegami T, Fujishiro M, Kawasaki M, Ikeda K, Amano H, Morimoto S, Ogawa H, Takamori K, Sekigawa I, Takasaki Y.

• 24. Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody. Biomed Res Int. 2013 (2013), 607137.

  Yanagida M, Kawasaki M, Fujishiro M, Miura M, Ikeda K, Nozawa K, Kaneko H, Morimoto S, Takasaki Y, Ogawa H, Takamori K, Sekigawa I.

• 25. Inhibition of connective tissue growth factor ameliorates disease in a murine model of rheumatoid arthritis. Arthritis Rheum. 2013 Jun;65(6): 1477-86.

  Nozawa K, Fujishiro M, Kawasaki M, Yamaguchi A, Ikeda K, Morimoto S, Iwabuchi K, Yanagida M, Ichinose S, Morioka M, Ogawa H, Takamori K, Takasaki Y, Sekigawa I.

• 26. Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with etanercept, a chimeric tumor necrosis factor-alpha receptor. Int J Rheum Dis. 2012 Oct; 15(5): 486-95.

  Yanagida M, Jung G, Tanaka Y, Sone S, Fujishiro M, Ikeda K, Nozawa K, Kaneko H, Takasaki Y, Ogawa H, Takamori K, Sekigawa I.

• （その他参照先https://researchmap.jp/read0162212）

著書

• 1. 抗MDA5抗体陽性皮膚筋炎に合併した急速進行性間質性肺炎とCOVID-19感染症による肺炎の類似性.リウマチ科（科学評論社）第67巻2号:202-209、2022

• 2. 従来型抗リウマチ薬（csDMARDs）．ここが知りたい！膠原病診療ハンドブック（中外医学社）123-128、2021.

• 3. 皮膚筋炎・多発性筋炎．ここが知りたい！膠原病診療ハンドブック（中外医学社）214-221、2021.

• 4. 痛風と偽痛風、対応できますか？. むかしの頭で診ていませんか？総合内科診療をスッキリまとめました（南江堂）183-189、2021.

• （その他参照先https://researchmap.jp/read0162212）

受賞

• 1. 2001年　順天堂大学医師会 ベストクリニカルフェロー賞

その他

• 【テレビ出演】1. 2011年　NHKクローズアップ現代“女性パワーがスポーツを変える”出演

• 【その他】1. 2015年　リウマチ診療支援システムの（株）DTS社との共同開発・販売プレスリリース